Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

Table 4 Comparison of outcomes between the mPSL alone and rTM groups after the stabilised IPTW

	Odds ratio^b	95% CI	p value
Logistic regression analyses of patients in the rTM and mPSL alone groups after the stabilised IPTW
All patients
In-hospital mortality	1.15	0.71–1.84	0.57
14-day mortality	0.80	0.48–1.32	0.38
28-day mortality	0.79	0.53–1.19	0.26
Bleeding events^a	1.60	0.70–3.64	0.27
Survivors
Bleeding events^a	0.33	0.04–2.68	0.30

	Incidence rate ratio^c	95% CI	p value
Incidence rate ratios of length of hospital stay in the rTM and mPSL alone groups after the stabilised IPTW
All patients
Length of hospital stay	1.18	0.93–1.50	0.18
Survivors
Length of hospital stay	1.34	0.95–1.92	0.098

rTM recombinant human soluble thrombomodulin, mPSL methylprednisolone, IPTW inverse probability of treatment weighting, CI confidence interval
^aBleeding events included epistaxis, hemoptysis, pulmonary hemorrhage, subcutaneous hemorrhage, purpura, muscle hemorrhage, hematuria, gastrointestinal bleeding, bloody stool and intracranial hemorrhage
^bThe odds ratio of the rTM group compared to the mPSL alone group
^cThe incidence rate ratio of the rTM group compared to the mPSL alone group

ISSN: 2052-0492